Medica Venture Partners

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

InterCure Ltd. is a medical device company that specializes in the development of innovative technologies for the treatment of cardiovascular and pulmonary diseases. Founded in 1994 and based in Hadera, Israel, InterCure has created a patented technology platform known as "Interactive Respiratory-Pacing." This platform has led to the development of product lines that offer non-drug treatments for prevalent conditions such as hypertension and heart failure. The company's flagship product, RESPeRATE, is the only FDA-cleared medical device shown to effectively reduce high blood pressure without side effects. Additionally, InterCure's heart failure treatment, InTone™, has successfully completed phase 2a clinical trials and is awaiting regulatory approval for market launch. With a strong management team and an esteemed Scientific Advisory Board, InterCure aims to lead the market in patient-focused medical devices that address significant health challenges without reliance on pharmaceuticals.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.

Orex Computed Radiography manufactures computerized radiography solutions. The company’s products includes Kodak Point-of-Care CR120, CR140, and CR260 that enables medical practitioners to acquire patient digital x-ray images from around the world. KODAK Point-of-Care CR-ITX 560 is a solution system that brings digital x-ray imaging directly to the patient. KODAK CR 7400 Digital Radiography is a system that delivers intraoral and extra oral images digitally. Orex Computed Radiography is an Israel-based company that was founded in 1996. The company was acquired by Kodak on January 19, 2005.

InterCure Ltd. is a medical device company that specializes in the development of innovative technologies for the treatment of cardiovascular and pulmonary diseases. Founded in 1994 and based in Hadera, Israel, InterCure has created a patented technology platform known as "Interactive Respiratory-Pacing." This platform has led to the development of product lines that offer non-drug treatments for prevalent conditions such as hypertension and heart failure. The company's flagship product, RESPeRATE, is the only FDA-cleared medical device shown to effectively reduce high blood pressure without side effects. Additionally, InterCure's heart failure treatment, InTone™, has successfully completed phase 2a clinical trials and is awaiting regulatory approval for market launch. With a strong management team and an esteemed Scientific Advisory Board, InterCure aims to lead the market in patient-focused medical devices that address significant health challenges without reliance on pharmaceuticals.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.